phathompharma.com (PHAT) - הכנסות ממכירות החברה

The commercialization of Voquezna provides Phathom Pharmaceuticals (PHAT) with a steady cash flow and high-quality earnings. The company's consolidated sales on this chart demonstrate actual revenue stripped of market noise, where the value of 0.27 expresses the metric level. Innovative drugs for acid-related pathologies enable the company to maintain pricing power. This patented blockbuster is effectively displacing legacy standards of care, expanding the issuer's market share.

For Phathom Pharmaceuticals (PHAT), whose revenue depends on a single GI drug, this indicator serves as the primary measure of commercial success. The metric aggregates all actual cash inflows from product sales over the reporting period. By analyzing the company's annual sales volume, an investor assesses the pace of insurance coverage expansion. Steady growth confirms the product's market potential, while sharp fluctuations on the chart signal systemic risks associated with a single-product model.